Reporter, Medtech Insight
Graduating in 2020 with a Master’s degree in biomedical engineering from University College London, Barnaby is passionate about all things medtech. In his first role as a journalist, Barnaby will focus on R&D and commercial stories in medtech, and writing about emerging technologies such as digital health, artificial intelligence, machine learning, deep-brain implants, and nanoscale applications of medtech. Alongside this, Barnaby is looking forward to taking deeper dives into start-ups, device market analysis, and company financial data, to create informed, useful, and engaging content.
Barnaby lives in in rural Wiltshire, UK and is a keen reader, cyclist, and hobbyist jeweler.
Latest From Barnaby Pickering
SonALAsense has received Safe to Proceed letters from the FDA to begin trials of its ultrasound-activated cancer killing drug.
A selection of articles you might have missed from June 2022, including a deep dive into venture finance, an in depth discussion about Russia's upcoming drug supply woes, and the latest Rising Leaders interviews.
The Memorial Sloan Kettering spin-out has received CE-IVD and UKCA marks for its artificial intelligence software designed to identify HER2 expression in biopsies.
Nothing except a name, but Creo Medical says its Speedboat Inject device can turn some surgeries from prolonged hospital stays into one-day visits.
In this episode of Report Digest, UK-based reporter Barnaby Pickering speaks to analyst Mike Carmody about Meddevicetracker’s recent report on deep brain and Vagus nerve stimulation. The two discuss market players, recent tech developments and future potential for the market.
Flagship products like Dexcom’s G7 and Abbott’s FreeStyle Libre 3 offer currently unrivalled accuracy of blood glucose measurement. However, as truly noninvasive technologies improve, the future basis for these companies’ growth is on shaky ground.